RJA
ATYR

Raymond James & Associates’s aTyr Pharma ATYR Stock Holding History

Raymond James & Associates’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-24,584
Closed -$184K – 4292
2021
Q4 		$184K Buy
+24,584
New +$205K ﹤0.01% 3725

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Raymond James & Associates's ATYR Position: Q1 2022 in Review

Raymond James & Associates sold out of aTyr Pharma (ATYR) in Q1 2022, closing a stake of 24,584 shares — an estimated $184K sold.

Raymond James & Associates first reported a position in ATYR in Q4 2021 and held it in 1 quarter. The position peaked at $184K in Q4 2021. 41 funds tracked by Wall St. Rank hold ATYR as of Q1 2022.

  • Raymond James & Associates reported no remaining aTyr Pharma position as of Q1 2022 after selling out during the quarter.
  • Raymond James & Associates sold 24,584 aTyr Pharma shares in Q1 2022, an estimated $184K.
  • Raymond James & Associates first reported a position in aTyr Pharma in Q4 2021 and held it in 1 quarter.
  • Raymond James & Associates's aTyr Pharma position peaked at $184K in Q4 2021.
  • 41 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2022.

Based on Raymond James & Associates's 13F filing for Q1 2022, filed 11 May 2022.